IDEAYA Biosciences Inc at Guggenheim Healthcare Talks Oncology Day Transcript
Good morning, everyone. I am Charles Zhu, one of the senior biotech analysts here at Guggenheim Securities. For our next session, we'll be hosting a fireside chat with IDEAYA Biosciences.
Yujiro and Mike, thank you very much for joining us here today. We appreciate your attendance and participation. Perhaps just to get us started off, could you kick off with your company platform and pipeline, please?
Great. So thank you so much, Charles, for the kind invitation today. Mike and I will be both -- are participating today at the fireside chat. Yeah, and we'll look forward to the conversation today.
So IDEAYA, we were founded just over seven years ago with a core focus to build the industry leading synthetic lethality-focused precision medicine oncology company. Today, we have three clinical programs. Our most advanced program is darovasertib. Here, we're targeting to have a discussion with the FDA on a potential
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
